SHPH — Shuttle Pharmaceuticals Holdings Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Shuttle Pharmaceuticals Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.68 | 2.48 | 6.37 | 8.53 | 11.6 |
| Operating Profit | -1.68 | -2.48 | -6.37 | -8.53 | -11.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.15 | -3.03 | -6.59 | -9.14 | -11.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.15 | -3.03 | -6.59 | -9.14 | -11.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.15 | -3.03 | -6.59 | -9.14 | -11.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.26 | -3.1 | -6.59 | -9.14 | -11.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -19.8 | -46.6 | -82 | -72.4 | -7.37 |
| Dividends per Share |